*Transitioning to wholly owned program in June 2022
Sangamo’s novel technology and depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies. Whether through in-licensing, out-licensing, scientific collaborations or advancing our corporate development priorities, our collaborations extend the reach of our technology and accelerate the development of genomic medicines. These are some of the ways we deliver on our commitment to get new treatments to patients in need.
Biogen and Sangamo have a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.
Kite, a Gilead Company, and Sangamo are developing next-generation ex vivo cell therapies to treat cancer by using Sangamo’s zinc finger nuclease (ZFN) technology.
Mogrify and Sangamo have a collaboration and exclusive license agreement providing Sangamo with access to Mogrify’s cell conversion reprogramming technology, which Sangamo expects will accelerate its development of scalable and accessible CAR-Treg cell therapies.
Novartis and Sangamo have a global licensing collaboration agreement to develop and commercialize gene regulation therapies to address neurodevelopmental targets, including genes linked to autism spectrum disorder and other neurodevelopmental disorders.
Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia. Sangamo and Pfizer are also collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
Sanofi and Sangamo are developing gene-edited cell therapy for the treatment of sickle cell disease, using Sangamo’s zinc finger nuclease technology. The program will be transitioned back to Sangamo in June 2022.
Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.
Contact Mark McClung, Executive Vice President, Chief Operating Officer